Search clinical trials for: Rolapitant

Total 12 results

Tesaro, Inc.

Completed

An Open-Label, Randomized, Pivotal, Bioequivalence Study of Oral and Intravenous Rolapitant

Chemotherapy-induced Nausea and Vomiting

United States
Merck Sharp & Dohme LLC

Completed

A Randomized Controlled Study of Rolapitant for the Prevention of Nausea and Vomiting Following Surgery (Study P04937AM1)(COMPLETED)

Postoperative Nausea and Vomiting
Tesaro, Inc.

Completed

A Phase 1, 2-Part, Single Ascending Dose Assessment of the Safety, Tolerability, and Pharmacokinetics of Rolapitant Intravenous in Healthy Volunteers

Chemotherapy-induced Nausea and Vomiting

United States
Merck Sharp & Dohme LLC

Completed

Study of the Efficacy and Safety of SCH 619734 in Subjects With Chronic Cough From an Unknown Cause (Study P04888)

Cough
Tesaro, Inc.

Completed

Ph3 Safety/Efficacy Study of Rolapitant for the Prevention of CINV in Subjects Receiving Highly Emetogenic Chemotherapy (HEC)

Chemotherapy-induced Nausea and Vomiting

United States
Tesaro, Inc.

Completed

Ph3 Safety/Efficacy Study of Rolapitant for the Prevention of CINV in Subjects Receiving Highly Emetogenic Chemotherapy

Chemotherapy-induced Nausea and Vomiting

United States
Tesaro, Inc.

Completed

Ph 3 Safety/Efficacy Study of Rolapitant for Prevention of CINV in Subjects Receiving Moderately Emetogenic Chemotherapy

Chemotherapy-induced Nausea and Vomiting

United States
Schering-Plough

Completed

A Multicenter, Randomized, Controlled Trial of SCH 619734 for the Treatment of Chemotherapy-Induced Nausea and Vomiting (Study P04351AM2)(COMPLETED)

Nausea | Vomiting
Duke University
TerSera Therapeutics

Completed

Rolapitant as an Antiemetic in Malignant Glioma Patients Receiving Radiotherapy and Temozolomide

Chemo-radiation Induced Nausea and Vomiting

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Terminated

Rolapitant Hydrochloride in Preventing Nausea/Vomiting in Patients With Sarcoma Receiving Chemotherapy

Locally Advanced Sarcoma

United States
Costantine Albany
Tesaro, Inc.

Withdrawn

Rolapitant Plus Olanzapine in Multiday Cisplatin Chemotherapy

Germ Cell Tumor
Tesaro, Inc.

Completed

An Open Label, Single Dose, Three Part Study to Assess the Effects of Rolapitant (2 mg/mL IV Solution) on the Pharmacokinetics of Digoxin; Sulfasalazine; and the Cooperstown Cocktail (Midazolam, Omeprazole, Warfarin, Caffeine, and Dextromethorphan in Healthy Subjects

Chemotherapy-induced Nausea and Vomiting

United States

3

Subscribe